PDL BioPharma, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for severe or life-threatening illnesses. The company’s products comprise Cardene for short-term treatment of hypertension; Retavase for use in the management of heart attacks in adults; and IV Busulfex, an intravenous formulation of busulfan, a chemotherapeutic agent for use in combination with cyclophosphamide as a conditioning regimen prior to bone marrow transplantation for chronic myelogenous leukemia. It offers these products through its sales force to the emergency cardiac, neurological, and intensive care units in hospitals in the United States and...